Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Lilly reported in December that its obesity drug had already met the main goal, leading to 47% more weight loss than those who received Wegovy. The data is the first head-to-head trial comparing the ...